VYNE Therapeutics (VYNE) Total Current Liabilities (2016 - 2026)

VYNE Therapeutics' Total Current Liabilities history runs 11 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Total Current Liabilities fell 89.94% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 89.94% YoY) and the FY2025 annual result came in at $2.4 million, down 83.84% from the prior year.
• Total Current Liabilities was $1.2 million for Q1 2026 at VYNE Therapeutics, down from $2.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.8 million in Q4 2024 and bottomed at $1.2 million in Q1 2026.
• A 5-year average of $8.1 million and a median of $7.5 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 96.59% — and 2026, when it slumped 89.94%.
• VYNE Therapeutics' Total Current Liabilities stood at $9.3 million in 2022, then retreated by 19.34% to $7.5 million in 2023, then jumped by 96.59% to $14.8 million in 2024, then tumbled by 83.84% to $2.4 million in 2025, then sank by 48.39% to $1.2 million in 2026.
• Business Quant data shows VYNE's Total Current Liabilities at $1.2 million in Q1 2026, $2.4 million in Q4 2025, and $5.8 million in Q2 2025.